Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels.

In IBD patients under ADA maintenance therapy who experience a secondary loss of response and in whom trough levels are >4.9µg/mL, swapping to another class is better than optimizing ADA, which is, however, appropriate in a subgroup of patients.